These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9836677)

  • 1. Secondary prevention in coronary heart disease. Cost effectiveness of treatment must be borne in mind.
    Ferner RE
    BMJ; 1998 Dec; 317(7172):1592. PubMed ID: 9836677
    [No Abstract]   [Full Text] [Related]  

  • 2. Coronary heart disease prevention: insights from modelling incremental cost effectiveness.
    Marshall T
    BMJ; 2003 Nov; 327(7426):1264. PubMed ID: 14644970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary prevention in coronary heart disease. Effects of statins have been in addition to those of aspirin and beta blockers.
    Morrell J
    BMJ; 1999 May; 318(7195):1419-20. PubMed ID: 10334767
    [No Abstract]   [Full Text] [Related]  

  • 4. Simvastatin: building on success.
    Gaw A
    Hosp Med; 2001 Jan; 62(1):29-32. PubMed ID: 11211458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial.
    Jönsson B; Cook JR; Pedersen TR
    Diabetologia; 1999 Nov; 42(11):1293-301. PubMed ID: 10550412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin therapy in nephrotic syndrome.
    Chan NN
    J R Soc Med; 1999 Mar; 92(3):158. PubMed ID: 10396279
    [No Abstract]   [Full Text] [Related]  

  • 7. Statins: where are we now?
    Cowie MR
    Hosp Med; 2000 Nov; 61(11):789-92. PubMed ID: 11198749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
    Jolain B; Pettitt D
    Clin Ther; 1995; 17(3):572-80. PubMed ID: 7585861
    [No Abstract]   [Full Text] [Related]  

  • 9. Royal College of Physicians of Edinburgh Consensus Conference on lipid lowering to prevent vascular events 17 & 18 March 1999.
    Scott Med J; 1999 Jun; 44(3):73-4. PubMed ID: 10461692
    [No Abstract]   [Full Text] [Related]  

  • 10. Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease.
    Goa KL; Barradell LB; McTavish D
    Pharmacoeconomics; 1997 Jan; 11(1):89-110. PubMed ID: 10172918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-lowering therapy for the primary prevention of coronary heart disease.
    Gotto AM
    J Am Coll Cardiol; 1999 Jun; 33(7):2078-82. PubMed ID: 10362217
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness of statins.
    Reckless JP
    Curr Opin Lipidol; 2000 Aug; 11(4):351-6. PubMed ID: 10945715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Guideline for management of lipid metabolism].
    Ishibashi S
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():675-8. PubMed ID: 12387068
    [No Abstract]   [Full Text] [Related]  

  • 14. Primary prevention of cardiovascular disease: implications of lipid-lowering trials.
    Pedersen TR
    J Hypertens Suppl; 1996 Dec; 14(5):S195-200. PubMed ID: 9120679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.
    Peura P; Martikainen J; Soini E; Hallinen T; Niskanen L
    Curr Med Res Opin; 2008 Jun; 24(6):1823-32. PubMed ID: 18485270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipids and prevention in coronary care.
    Betteridge DJ
    Trans Med Soc Lond; 1994-1995; 111():43-58. PubMed ID: 9156156
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pharmaco-economics of hypolipidemic agents: analysis of factors influencing the cost-effectiveness relation].
    Scheen AJ
    Rev Med Liege; 1998 May; 53(5):270-5. PubMed ID: 9689881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of statins. Sheffield table is useful.
    Ramsay LE; Wallis EJ; Haq IU; Williamson R; Yeo WW; Jackson PR
    BMJ; 1998 Aug; 317(7156):473-4. PubMed ID: 9703541
    [No Abstract]   [Full Text] [Related]  

  • 19. Rationale, design, and baseline results of the Pravastatin-to-Simvastatin Conversion Lipid Optimization Program (PSCOP).
    Ito MK; Stolley SN; Morreale AP; Lin JC; Marcus DB
    Am J Health Syst Pharm; 1999 Jun; 56(11):1107-13. PubMed ID: 10385458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic prevention of coronary artery disease. What do clinical trials show?
    Milani RV; Lavie CJ
    Postgrad Med; 1996 Feb; 99(2):109-12, 115-20. PubMed ID: 8632961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.